Female Infertility Evaluation & Management
Clinical detail
Additional detail checked 2026-10-17 against the linked sources. This check covers the section below; the rest of the module retains its displayed verification status.
Assess fertility as a couple or reproductive partnership. A female-factor pathway should not delay semen assessment or assume that irregular cycles are the only possible contributor.
Assessment & interpretation
- Review the duration of attempts, cycle pattern, sexual and reproductive history, previous pregnancy, infection, surgery and known risk factors.
- Use the current NICE initial-assessment pathway to decide timing of investigation and earlier referral; investigate relevant male and female factors in parallel.
- Interpret ovarian-reserve tests for the specific treatment question. They do not by themselves predict whether spontaneous conception will occur.
Decisions that change management
- Confirm whether ovulation is occurring and select endocrine tests from the history; assess tubal patency and uterine factors when indicated.
- Known endometriosis, suspected tubal disease or anovulation changes the investigation and treatment pathway.
- Discuss aetiology-specific treatment after assessment, rather than offering repeated empirical ovulation induction without checking other contributors.
Follow-up & safety-netting
- Explain test results, realistic next steps and when to return. Include emotional support, preconception health and the risks of treatment.
- Fertility care involving ovarian stimulation requires counselling and monitoring for multiple pregnancy and ovarian hyperstimulation.
Admission & discharge
Admission/discharge guidance checked 2026-10-18 against the linked sources. This is a clinical checklist for an individual decision, not an automatic discharge order.
When admission or continued hospital care is needed
- Severe OHSS, pain not controlled by oral treatment, persistent vomiting/dehydration, reduced urine, breathing/chest symptoms, thrombosis concern or inability to attend monitoring may require admission.
- Acute pain/bleeding after treatment also requires assessment for ectopic pregnancy, torsion or procedural injury.
When clinic, day care or home care may be suitable
- Infertility assessment and most monitored treatment are outpatient services; arrange partner evaluation and the indicated diagnostic pathway.
Before going home
- Pain/intake, urine output, observations and relevant renal/haematological findings support home care; the fertility team has agreed monitoring and emergency access.
- Do not discharge significant OHSS with a generic pain prescription but no fluid, urine, thrombosis and review plan.
Discharge medicines and treatment changes
- Reconcile the exact fertility medicines and any VTE prevention with the treating unit; avoid NSAIDs in OHSS because of renal risk.
Tests, pending results and their reviewer
- Assign pregnancy testing, imaging and any OHSS blood/organ tests to the fertility service with exact review dates.
Home care and counselling
- Explain fluid intake according to thirst, symptoms/urine monitoring, activity and the treating unit’s contact arrangements; provide postoperative advice if a procedure occurred.
Follow-up: when and what to review
| When | Action / responsible service |
|---|---|
At the booked monitored-cycle/OHSS review | Reassess symptoms, urine/fluid balance and tests; confirm the next contact before leaving. |
After a positive pregnancy test | Follow the early-pregnancy location/viability pathway, especially with pain or bleeding. |
Return urgently
- Worsening pain/distension, vomiting, reduced urine, chest pain, breathlessness, leg symptoms or fainting requires urgent hospital assessment.
Treatment
① Immediate stabilization — first minutes
Not acute; structured timed-cycle clinic.
③ First-line treatment & drug regimens
| Cause | Treatment ladder |
|---|---|
Anovulatory (WHO II/PCOS) | Letrozole first-line -> clomiphene/metformin combos -> low-dose gonadotrophins -> IVF |
Unexplained | Expectant/IUI ± OS -> IVF after failed cycles |
Tubal disease | IVF primary; salpingectomy (hydrosalpinx) improves IVF outcomes |
Endometriosis-associated | Surgery then individualised ART timing |
Diminished reserve/poor response | Counselling + tailored protocols/oocyte considerations |
Definitive treatment
ART escalation per ladder; donor/gestational pathways counselled where applicable.
Monitoring
- OI cycles monitored to prevent multiples/OHSS
Response assessment
- Monofollicular ovulation; clinical pregnancy milestones
Treatment failure
- Failed OI lines -> escalate per ladder
Second-line treatment
- Gonadotrophins/IUI/IVF sequences above
Rescue treatment
Procedure / surgery
Oocyte-retrieval/transfer pages queued v1.1.
⑮ Complications & their management
Multiple pregnancy
Monofollicular targets; single-embryo transfer policies
Post-treatment care
- Early-pregnancy support after conception (bleeding/miscarriage anxiety)
Diagnosis & assessment
Initial assessment
- History: cycle regularity, HSG-relevant infection history, surgeries, BMI
- Semen analysis x2 for partner (always early!)
- Day-21 progesterone / LH kits confirming ovulation
- AMH/AFC as context (not destiny)
- HSG or hyCoSy for tubal patency
Investigations
| Test | Looking for |
|---|---|
Semen analysis (WHO reference limits) | Male factor triage |
HSG | Tubal blockage/proximal filling defects |
Sources (9)
2023 (Eur J Endocrinol 189(2):G43–G64) · checked 2026-08-23 · verified-live
Open source ↗
Guideline recommendation extracts: letrozole first-line pharmacological ovulation induction (off-label caveat); clomiphene > metformin alone; gonadotrophins second line low-dose step-up; laparoscopic ovarian surgery alternative second line; IVF after failed 1st/2nd line with antagonist protocol + ag…
31 March 2026 · checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for infertility-female. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/dischar…
31 March 2026 · checked 2026-10-18 · verified-live
Open source ↗
Scope: additional clinical-detail explanation for infertility-female. Checked the assessment, management-decision and follow-up statements in that section against this source. This does not certify all pre-existing regimens, calculations or recommendations in the module. Additional admission/dischar…
· checked 2026-10-18 · verified-summary
Open source ↗
Primary information read: mild OHSS may be managed at home; uncontrolled pain/vomiting, failure to improve or inability to attend monitoring can require admission; urine/fluid/renal/thrombosis assessment and avoiding NSAIDs. Edition is 2016, not a newly issued 2026 guideline; no universal anticoagul…
· checked 2026-10-18 · verified-live
Open source ↗
Maternal/newborn transfer assessment, first void and effective feeding, handover, support/safeguarding, first midwife visit within 36 hours after transfer, postnatal danger symptoms. Full recommendations page read.
· checked 2026-10-18 · verified-live
Open source ↗
Normal-delivery discharge not less than 48 hours: full primary SOP PDF normal-delivery/discharge passages read. Corroborated by NHM CEmONC 2024 Part 1, chapter 8. This does not define a universal post-caesarean or complicated-case stay.
· checked 2026-10-18 · verified-live
Open source ↗
Official WHO summary read: at least 24-hour facility care after birth; additional contacts at 48–72 hours, 7–14 days and week 6; individual assessment/support. Summary facts only, not a claim that the full 242-page PDF was reviewed.
· checked 2026-10-18 · verified-live
Open source ↗
Full primary patient recovery page read: pain control, wounds, activity/VTE, urinary/bowel and infection warning signs, adult support and no driving/important decisions during the first 24 hours after general anaesthesia. Used as general recovery/handover principles, not operation-specific discharge…
· checked 2026-10-18 · verified-live
Open source ↗
Full primary recommendations read, focusing on critical-care-to-ward transfer: structured written handover, shared plan, monitoring, rehabilitation and receiving-team capability. Step-down is distinct from home discharge; no universal organ-support discharge cutoff is asserted.